Aldeyra Therapeutics (NASDAQ: ALDX) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Aldeyra Therapeutics to related businesses based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.


This table compares Aldeyra Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aldeyra Therapeutics N/A -80.41% -70.58%
Aldeyra Therapeutics Competitors -5,527.51% -454.18% -42.48%

Analyst Ratings

This is a summary of current ratings for Aldeyra Therapeutics and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aldeyra Therapeutics 0 0 4 0 3.00
Aldeyra Therapeutics Competitors 760 3020 11160 227 2.72

Aldeyra Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 195.28%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.04%. Given Aldeyra Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Aldeyra Therapeutics is more favorable than its peers.

Risk and Volatility

Aldeyra Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics’ peers have a beta of 6.62, meaning that their average share price is 562% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aldeyra Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Aldeyra Therapeutics N/A -$19.82 million -4.35
Aldeyra Therapeutics Competitors $260.16 million $66.28 million -6.75

Aldeyra Therapeutics’ peers have higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

40.3% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.4% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with's FREE daily email newsletter.